Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry end­point

Dis­cov­ery Life Sci­ences has ac­quired what claims to be the Mary­land-based host of the world’s largest he­pa­to­cyte in­ven­to­ry, known as IVAL, to help re­searchers se­lect more ef­fec­tive and safer drug can­di­dates in the fu­ture.

The com­bined com­pa­nies will now serve a wider range of drug re­search and de­vel­op­ment sci­en­tists, ac­cord­ing to Al­bert Li, who found­ed IVAL in 2004 and is set to join the Dis­cov­ery lead­er­ship team as the CSO of phar­ma­col­o­gy and tox­i­col­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.